Drugs Affecting Blood and Blood Formation Practice Questions

Q: Microcytic hypochromic anemia due to inadequate nutrition is best treated with:

Oral ferrous sulfate. **Explanation:** **1. Why Oral Ferrous Sulfate is Correct:** Microcytic hypochromic anemia is the hallmark of **Iron Deficiency Anemia (IDA)**. In cases of inadequate nutrition, the primary goal is to replenish iron stores. **Oral ferrous salts** (divalent iron) are the treatment of choice because iron is absorbed from the gastrointestinal tract in the ferrous ($Fe^{2+}$) state. Ferrous sulfate is the most commonly prescribed preparation due to its high elemental iron content (approx. 20%), cost-effectiveness, and proven efficacy in raising hemoglobin levels. **2. Why the Other Options are Incorrect:** * **Oral Ferric Chloride:** Ferric iron ($Fe^{3+}$) must be converted to the ferrous state by gastric acid and ferrireductase before absorption. Ferric salts are generally less soluble at alkaline pH and have significantly lower bioavailability compared to ferrous salts. * **Vitamin B12 (Oral/IM):** Vitamin B12 deficiency causes **Megaloblastic (Macrocytic) Anemia**, characterized by an increased Mean Corpuscular Volume (MCV). It would not be effective for microcytic (low MCV) anemia. **3. NEET-PG High-Yield Pearls:** * **Absorption:** Iron is primarily absorbed in the **duodenum and upper jejunum**. Absorption is enhanced by Vitamin C (ascorbic acid) and inhibited by phosphates, phytates (cereals), and tetracyclines. * **Response to Therapy:** The earliest indicator of response to iron therapy is a **rise in reticulocyte count**, peaking at 5–10 days. Hemoglobin typically rises by 2 g/dL every 3 weeks. * **Side Effects:** The most common side effects of oral iron are GI-related (nausea, epigastric pain, constipation, and black stools). * **Parenteral Iron:** Reserved for patients with malabsorption, intolerance to oral iron, or chronic kidney disease (e.g., Iron Sucrose or Ferric Carboxymaltose).

Q: Low molecular weight heparin acts on which coagulation factor?

Factor Xa. **Explanation:** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin and Dalteparin, are derived from the fractionation of Unfractionated Heparin (UFH). Their mechanism of action involves binding to **Antithrombin III (AT-III)**, inducing a conformational change that accelerates the inactivation of coagulation factors. The key distinction lies in the molecular chain length. To inactivate **Factor Xa**, only the pentasaccharide sequence of heparin is required to bind to AT-III. However, to inactivate **Thrombin (Factor IIa)**, the heparin chain must be long enough (at least 18 saccharide units) to bridge AT-III and Thrombin together. LMWH chains are shorter; therefore, they efficiently catalyze the inhibition of Factor Xa but have significantly less effect on Factor IIa (ratio of Xa:IIa activity is typically 3:1 or 4:1). **Analysis of Options:** * **Option B (Correct):** LMWH primarily inhibits Factor Xa due to its specific molecular structure. * **Option D (Incorrect):** While Unfractionated Heparin (UFH) inhibits both IIa and Xa equally (1:1 ratio), LMWH has minimal activity against Factor IIa. * **Options A & C (Incorrect):** Factors XIa and IXa are inhibited by the Heparin-AT-III complex to a much lesser extent and are not the primary targets for LMWH. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Unlike UFH, LMWH does not require routine aPTT monitoring due to a predictable dose-response. If monitoring is needed (e.g., in renal failure or pregnancy), **Anti-Factor Xa levels** are measured. * **Elimination:** LMWH is primarily excreted **renally**; thus, it is contraindicated or requires dose adjustment in chronic kidney disease (UFH is preferred here). * **Antidote:** Protamine sulfate only partially reverses LMWH (approx. 60-75%), whereas it fully reverses UFH. * **Advantage:** LMWH has a lower risk of Heparin-Induced Thrombocytopenia (HIT) and osteoporosis compared to UFH.

Q: Which of the following prevents plasminogen activators?

Aminocaproic acid. ### Explanation The correct answer is **Aminocaproic acid**. **Mechanism of Action:** Aminocaproic acid (and its more potent analog, Tranexamic acid) is an **antifibrinolytic agent**. It acts as a lysine analog that binds to the lysine-binding sites on **plasminogen and plasmin**. By doing so, it competitively inhibits the binding of plasminogen to fibrin and prevents its conversion into active plasmin by plasminogen activators (like tPA or urokinase). Ultimately, it inhibits fibrinolysis and stabilizes clots. **Analysis of Incorrect Options:** * **A. Streptokinase:** This is a **fibrinolytic (thrombolytic)** agent. It is a protein derived from streptococci that binds with plasminogen to form an active complex, which then converts free plasminogen into plasmin to dissolve clots. * **C. Reteplase:** This is a recombinant **tissue plasminogen activator (tPA)**. Like Alteplase and Tenecteplase, it directly activates plasminogen to promote clot lysis. It is used in the management of acute myocardial infarction. * **D. Clopidogrel:** This is an **antiplatelet drug**. It works by irreversibly blocking the **P2Y12 receptor** for ADP on the platelet surface, preventing platelet aggregation. It has no direct effect on the plasminogen system. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Uses:** Aminocaproic acid is used to treat bleeding associated with hyperfibrinolysis, such as post-prostatectomy bleeding, tooth extraction in hemophiliacs, or thrombolytic overdose. * **Tranexamic Acid (TXA):** It is 7–10 times more potent than aminocaproic acid and is the preferred agent in trauma and heavy menstrual bleeding (menorrhagia). * **Side Effects:** A significant risk of antifibrinolytics is the potential for **thrombosis** (DVT/PE) and, specifically for aminocaproic acid, **myopathy/rhabdomyolysis**.

Q: Heparin does not cause which of the following?

Factor V inhibition. ### Explanation **Correct Answer: B. Factor V inhibition** **Mechanism of Action:** Heparin acts by binding to **Antithrombin III (AT-III)**, which induces a conformational change that accelerates the inactivation of various clotting factors. Heparin primarily inhibits **Thrombin (Factor IIa)** and **Factor Xa**. It also inhibits Factors IXa, XIa, and XIIa. **Factor V** is a cofactor, not a serine protease; therefore, it is **not** directly inhibited by the Heparin-AT III complex. **Analysis of Incorrect Options:** * **A. Osteoporosis:** Long-term heparin therapy (usually >3–6 months) can lead to decreased bone density and osteoporosis. This occurs because heparin stimulates osteoclasts and inhibits osteoblast activity. * **C. Thrombocytopenia:** Heparin-Induced Thrombocytopenia (HIT) is a significant side effect. Type II HIT is an immune-mediated reaction where antibodies form against the Heparin-Platelet Factor 4 (PF4) complex, leading to paradoxically increased thrombosis and low platelet counts. * **D. Prolongation of aPTT:** The activated Partial Thromboplastin Time (aPTT) measures the intrinsic and common pathways. Since heparin inhibits Factors II, IX, X, XI, and XII, it significantly prolongs aPTT, which is the standard test for monitoring Unfractionated Heparin (UFH). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Protamine sulfate (a basic protein that neutralizes acidic heparin). * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa and has a lower risk of HIT and osteoporosis compared to UFH. * **Monitoring:** UFH is monitored by **aPTT**, while LMWH monitoring (if required) is done via **Anti-Xa levels**. * **Safe in Pregnancy:** Heparin does not cross the placenta, making it the anticoagulant of choice during pregnancy.

Q: What is true about iron?

Absorption of iron is increased by ascorbic acid.. **Explanation:** **1. Why Option D is Correct:** Iron absorption occurs primarily in the duodenum and upper jejunum. Dietary iron exists in two forms: Heme and Non-heme (ferric, $Fe^{3+}$). For non-heme iron to be absorbed, it must be in the **ferrous ($Fe^{2+}$) state**. **Ascorbic acid (Vitamin C)** acts as a reducing agent that converts ferric iron to ferrous iron and forms a soluble chelate, significantly enhancing its absorption. Conversely, phosphates, phytates, and tea (tannins) inhibit absorption. **2. Why Other Options are Incorrect:** * **Option A:** Parenteral iron is **not** indicated for a "slow response." The rate of hemoglobin rise is generally the same for both oral and parenteral routes. Indications for parenteral iron include oral intolerance, malabsorption (e.g., Celiac disease), or when rapid replenishment of stores is needed (e.g., late pregnancy). * **Option B:** Ferrous sulfate contains **20%** elemental iron (200mg $\approx$ 60mg iron), whereas Ferrous gluconate contains only **12%** (200mg $\approx$ 24mg iron). Thus, sulfate has *more* elemental iron. * **Option C:** Sustained-release (SR) formulations are generally **discouraged**. Iron is best absorbed in the duodenum; SR preparations often bypass this "absorption window," releasing iron in the distal small intestine where absorption is poor. **High-Yield Clinical Pearls for NEET-PG:** * **Oral Iron:** Best taken on an empty stomach for maximum absorption, though often taken with food to reduce GI side effects (gastritis, metallic taste). * **Parenteral Iron:** Iron Dextran carries a risk of **anaphylaxis** (requires a test dose). Iron Sucrose and Ferric Carboxymaltose are safer alternatives. * **Toxicity:** Acute iron poisoning is treated with **Deferoxamine** (IV). Chronic iron overload (hemosiderosis) is treated with **Deferiprone** or **Deferasirox** (Oral).

Q: Purple toe syndrome is associated with which of the following drugs?

Warfarin. **Explanation:** **Purple Toe Syndrome** is a rare but classic clinical complication associated with **Warfarin** therapy. 1. **Why Warfarin is correct:** The underlying mechanism is believed to be **cholesterol microembolization**. Warfarin-induced anticoagulation can cause the friable atherosclerotic plaques in the aorta or proximal arteries to bleed or destabilize. This releases small cholesterol crystals that travel distally and lodge in the small capillaries of the toes, leading to livedo reticularis, pain, and a characteristic purple-blue discoloration. It typically occurs 3 to 8 weeks after starting therapy. 2. **Why the other options are incorrect:** * **Phenytoin:** Known for causing gingival hyperplasia, hirsutism, and fetal hydantoin syndrome, but not peripheral embolic phenomena. * **Theophylline:** Toxicity primarily manifests as gastrointestinal upset, seizures, and cardiac arrhythmias due to its narrow therapeutic index. * **Thalidomide:** Famous for its teratogenic effect (**Phocomelia** or seal-like limbs). While it can cause peripheral neuropathy, it does not cause purple toe syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Warfarin-induced Skin Necrosis:** Another dermatological emergency caused by Warfarin, occurring much earlier (days 3–10) due to a rapid decline in **Protein C** levels, leading to a transient hypercoagulable state. * **Management:** If purple toe syndrome occurs, Warfarin must be discontinued. * **Antidote:** For Warfarin overdose, use **Vitamin K** (slow) or **Prothrombin Complex Concentrate (PCC)/Fresh Frozen Plasma** (rapid). * **Teratogenicity:** Warfarin is contraindicated in pregnancy as it causes **Chondrodysplasia punctata** (stippled epiphyses and nasal hypoplasia).

Q: Which of the following is NOT used in the management of Myocardial Infarction?

Plasminogen activator inhibitor. In the management of Myocardial Infarction (MI), the primary goal is to restore coronary blood flow by breaking down or preventing the formation of an occlusive thrombus. **Explanation of the Correct Answer:** **B. Plasminogen activator inhibitor (PAI-1):** This is an endogenous protein that **inhibits** fibrinolysis by blocking tissue plasminogen activator (tPA). Administering a PAI-1 would prevent the breakdown of a clot, thereby worsening the ischemia in an MI. In clinical practice, drugs like **Tranexamic acid** and **Epsilon-aminocaproic acid** act as antifibrinolytics; these are used to stop bleeding (e.g., in surgery or trauma) and are strictly contraindicated in acute MI. **Explanation of Incorrect Options:** * **A. Fibrinolytics:** (e.g., Streptokinase, Alteplase, Tenecteplase) These are "clot busters" used in STEMI to dissolve the existing fibrin mesh of the thrombus. * **C. Antithrombin:** (e.g., Heparin, Enoxaparin, Fondaparinux) These prevent further thrombus propagation by inhibiting thrombin or Factor Xa, maintaining the patency of the vessel. * **D. Platelet inhibitor:** (e.g., Aspirin, Clopidogrel, Ticagrelor) Since the initial step of MI is platelet aggregation on a ruptured plaque, dual antiplatelet therapy (DAPT) is a cornerstone of management. **High-Yield NEET-PG Pearls:** * **Tenecteplase** is the fibrinolytic of choice in STEMI due to its high fibrin specificity and long half-life (bolus administration). * **Aspirin** should be chewed (not swallowed) in the emergency setting for faster absorption via the buccal mucosa. * **Absolute Contraindications for Fibrinolytics:** History of hemorrhagic stroke, active internal bleeding, or recent intracranial neoplasm.

Q: Vitamin B12 is given in severe anemia via which route?

Intramuscular. **Explanation:** The correct route for administering Vitamin B12 (Cyanocobalamin/Methylcobalamin) in cases of severe anemia is **Intramuscular (IM)** [1]. **1. Why Intramuscular (IM) is the Correct Choice:** In severe megaloblastic anemia or cases involving neurological symptoms (Subacute Combined Degeneration of the Cord), rapid restoration of B12 stores is critical [1]. The IM route ensures **100% bioavailability** and bypasses the gastrointestinal absorption barriers. Most clinical cases of severe B12 deficiency are caused by malabsorption (e.g., Pernicious anemia, Gastrectomy, or IBD), where the intrinsic factor is absent or the terminal ileum is damaged, making parenteral administration mandatory for effective replenishment [1]. **2. Analysis of Incorrect Options:** * **Intravenous (IV):** While possible, it is rarely preferred because Vitamin B12 is rapidly excreted by the kidneys when given IV. The IM route creates a "depot" effect, allowing for more sustained plasma levels. * **Oral:** In severe anemia, oral absorption is too slow and unreliable. While high-dose oral B12 can work via passive diffusion in mild cases, it is contraindicated in severe deficiency or when malabsorption is the primary etiology. * **All of the above:** Incorrect because the IM route is the established clinical standard for initial "loading doses" in severe presentations. **NEET-PG High-Yield Pearls:** * **Schilling Test:** Historically used to diagnose B12 malabsorption (now largely replaced by antibody testing). * **Hypokalemia Risk:** During the initial treatment of severe megaloblastic anemia, rapid erythropoiesis can lead to a sudden drop in serum potassium. **Monitor Potassium levels** during the first 48 hours of therapy. * **Maintenance:** Once stores are replenished, life-long IM injections (usually monthly) are required if the underlying cause is irreversible (e.g., Pernicious Anemia).

Q: Heparin is the most widely used antithrombotic agent. It acts by activating which of the following?

Antithrombin III. ### Explanation **Correct Option: B. Antithrombin III** Heparin is an indirect-acting anticoagulant. It works by binding to **Antithrombin III (AT-III)**, a natural plasma protease inhibitor. This binding induces a conformational change in AT-III, accelerating its activity by nearly 1,000-fold. The Heparin-AT-III complex then inactivates several clotting factors, primarily **Thrombin (Factor IIa)** and **Factor Xa**, as well as factors IXa, XIa, and XIIa. * **Unfractionated Heparin (UFH):** Inactivates both IIa and Xa. * **Low Molecular Weight Heparin (LMWH):** Primarily inactivates Factor Xa. --- ### Why Other Options are Incorrect: * **A & C (Plasmin/Fibrinolysin):** These are synonymous. Plasmin is the active enzyme responsible for **fibrinolysis** (breaking down an existing clot). Drugs that activate plasminogen to plasmin are called Thrombolytics (e.g., Streptokinase, Alteplase), not anticoagulants like Heparin. * **D (Factor X):** Heparin does not *activate* Factor X; it leads to its **inhibition**. Direct Factor Xa inhibitors (e.g., Rivaroxaban, Apixaban) act directly on this factor without requiring AT-III. --- ### High-Yield NEET-PG Pearls: 1. **Monitoring:** UFH is monitored using **aPTT** (intrinsic pathway). LMWH usually does not require monitoring but can be checked using **Anti-Xa levels**. 2. **Antidote:** The specific antagonist for Heparin overdose is **Protamine Sulfate** (a strongly basic protein that neutralizes acidic heparin). 3. **Side Effect:** A critical immune-mediated complication is **Heparin-Induced Thrombocytopenia (HIT)**, caused by antibodies against the Heparin-Platelet Factor 4 (PF4) complex. 4. **Safe in Pregnancy:** Heparin does not cross the placenta, making it the anticoagulant of choice during pregnancy.

Q: Epsilon aminocaproic acid (EACA) can be used in the treatment of adverse effects caused by which of the following agents?

Streptokinase. ### Explanation **1. Why Streptokinase is Correct:** Streptokinase is a **thrombolytic (fibrinolytic)** agent that works by converting plasminogen to plasmin. Plasmin is the enzyme responsible for degrading fibrin clots. Excessive plasmin activity can lead to systemic fibrinolysis and life-threatening hemorrhage. **Epsilon aminocaproic acid (EACA)** is an **antifibrinolytic** drug. It acts as a lysine analogue that competitively inhibits plasminogen activation and prevents plasmin from binding to fibrin. Therefore, EACA (along with Tranexamic acid) is the specific antidote used to reverse bleeding caused by thrombolytics like Streptokinase, Alteplase, or Urokinase. **2. Why Other Options are Incorrect:** * **Heparin (Option B):** Heparin is an anticoagulant that enhances the activity of Antithrombin III. Its specific pharmacological antagonist is **Protamine sulfate**. * **Warfarin (Option C):** Warfarin inhibits Vitamin K Epoxide Reductase (VKOR). Its effects are reversed using **Vitamin K1 (Phytonadione)** for slow reversal, or **Fresh Frozen Plasma (FFP)** and **Prothrombin Complex Concentrate (PCC)** for immediate reversal. * **Any of the above (Option D):** This is incorrect because EACA has a specific mechanism targeting the fibrinolytic pathway, not the coagulation cascade inhibited by Heparin or Warfarin. **3. High-Yield Clinical Pearls for NEET-PG:** * **Tranexamic Acid (TXA):** It is 7–10 times more potent than EACA and is more commonly used in clinical practice for trauma, menorrhagia, and postpartum hemorrhage. * **Mechanism Tip:** Remember that EACA/TXA block the **"Lysine Binding Sites"** on plasminogen. * **Contraindication:** EACA should be avoided in cases of upper urinary tract bleeding (e.g., hematuria) as it can cause unlysed clots leading to ureteral obstruction and acute renal failure. * **Aprotinin:** Another antifibrinolytic that acts by directly inhibiting plasmin (direct enzyme inhibitor).

Question 1

Microcytic hypochromic anemia due to inadequate nutrition is best treated with:

Accepted Answer

Oral ferrous sulfate

Answer

Oral ferric chloride

Answer

Oral vitamin B12

Answer

Intramuscular vitamin B12

Question 2

Low molecular weight heparin acts on which coagulation factor?

Accepted Answer

Factor Xa

Answer

Factor XIa

Answer

Factor IXa

Answer

Factor IIa

Question 3

Which of the following prevents plasminogen activators?

Accepted Answer

Aminocaproic acid

Answer

Streptokinase

Answer

Reteplase

Answer

Clopidogrel

Question 4

Heparin does not cause which of the following?

Accepted Answer

Factor V inhibition

Answer

Osteoporosis

Answer

Thrombocytopenia

Answer

Prolongation of aPTT

Question 5

What is true about iron?

Accepted Answer

Absorption of iron is increased by ascorbic acid.

Answer

Parenteral iron is indicated when anemia responds slowly to oral iron.

Answer

Ferrous sulfate 200mg has less elemental iron than the same dose of ferrous gluconate.

Answer

Sustained-release iron is a useful way of giving larger doses.

Question 6

Purple toe syndrome is associated with which of the following drugs?

Accepted Answer

Warfarin

Answer

Phenytoin

Answer

Theophylline

Answer

Thalidomide

Question 7

Which of the following is NOT used in the management of Myocardial Infarction?

Accepted Answer

Plasminogen activator inhibitor

Answer

Fibrinolytics

Answer

Antithrombin

Answer

Platelet inhibitor

Question 8

Vitamin B12 is given in severe anemia via which route?

Accepted Answer

Intramuscular

Answer

Intravenous

Answer

Oral

Answer

All of the above

Question 9

Heparin is the most widely used antithrombotic agent. It acts by activating which of the following?

Accepted Answer

Antithrombin III

Answer

Plasmin

Answer

Fibrinolysin

Answer

Factor X

Question 10

Epsilon aminocaproic acid (EACA) can be used in the treatment of adverse effects caused by which of the following agents?

Accepted Answer

Streptokinase

Answer

Heparin

Answer

Warfarin

Answer

Any of the above

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?